Ovarian Cancer Pipeline Analysis
“Ovarian Cancer Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles being developed for the treatment of Ovarian Cancer. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. Insight for each drug profile in development phase enables the reader to identify and understand the therapeutics associated with the Ovarian Cancer disease. The information for particular drug in development process is represented in the form of tables and detailed analysis including the available Pharmacodynamics and Pharmacokinetics results.
This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the drug development process. Report also helps drug development organisation to keep track record the ongoing drug profiles being developed by their key competitor in the industry.
Following parameters for each drug profile in development phase are covered in “Ovarian Cancer Pipeline Analysis” research report:
- Drug Profile Overview
- Active Indication
- Phase of Development
- Country for Clinical Trial
- Owner / Originator/ Licensee/Collaborator
- Administrative Route
- Drug Class
- Patent Information
- Molecular Formula
- Pharmodynamics
- Pharmacokinetics
- Brand Names
- Development Agreements
- ATC Codes
1.1 Overview
1.2 Drug Profile
2. DRUG PIPELINE: PHASE I
2.1 Overview
2.2 Drug Profile
3. DRUG PIPELINE: PHASE-I/II
3.1 Overview
3.2 Drug Profile
4. DRUG PIPELINE: PHASE-II
4.1 Overview
4.2 Drug Profile
5. DRUG PIPELINE: PHASE-II/III
5.1 Overview
5.2 Drug Profile
6. DRUG PIPELINE: PHASE-III
6.1 Overview
6.2 Drug Profile
7. DRUG PIPELINE: PREREGISTRATION
7.1 Overview
7.2 Drug Profile
Immunovaccine, Inc. (formerly ImmunoVaccine Technologies) is developing DPX 0907,a single-dose depot vaccine using its DepoVax™ vaccine platform for the treatment of breast, ovarian and prostate cancer. It comprises seven proprietary breast, ovarian,and prostate cancer HLA-A2-restricted antigens from Immunotope combined with Immunovaccine's DepoVax™ delivery platform. DepoVax™ consists of a target antigenand an adjuvant in a hydrophobic oil carrier encapsulated in a liposomal delivery system. The antigens in the vaccine stimulate T-cell recognition, and the destruction of cells with the cancer "signature". Immunovaccine believes that its vaccines will produce a depot effect that will significantly enhance vaccine-induced cell-mediatedand humoral immunity. The vaccine comes in a dry format that is easily reconstituted.A phase I clinical trial has been completed in the US.
In October 2009, ImmunoVaccine Technologies was acquired by Rhino Resources, acapital pool company. Subsequently, Rhino Resources changed its name to Immunovaccine, Inc.In July 2009, ImmunoVaccine Technologies (now Immunovaccine, Inc.) entered into anagreement with Immunotope to exclusively license 7 cancer antigens. The antigens target breast, ovarian, and prostate cancers. Immunovaccine will combine the antigens with its proprietary DepoVax™ delivery platform to develop a therapeutic cancervaccine (DPX 0907). Under terms of the licensing agreement, Immunotope will receivean upfront payment, milestones, and royalties.
In January 2013, Immunovaccine entered into an agreement to collaborate on aninvestigator-initiated phase I/II clinical trial of DPX 0907 in patients with breast andovarian cancer in Italy. The study will be conducted at the Busto Arsizio Hospital and will be the first trial of the drug in Europe. Trial initiation is expected in the fourth quarter of 2013.
Immunovaccine has completed a phase I trial in the US involving 23 patients with HLAA2-positive, advanced stage ovarian, breast, and prostate cancer (NCT01095848). The trial evaluated the safety and immunogenicity of two dosing regimens of DPX 0907(0.25mL or 1mL) in such patients. Results have been reported.
Results from animal studies have demonstrated that the DepoVax™ formulation used inDPX 0907 induces a more than two-fold reduction in the levels of immune suppressing cells such as Treg, MDSC, Tr1 and activated Treg cells located in the tumour and various lymphoid organs.Preclinical studies have shown that the DepoVax™ formulation used in DPX 0907promotes superior antigen-specific immune reponses, compared with other peptide vaccine delivery methods.
Financing information: in March 2011, Immunovaccine reported that it would receive$Can2.9 million from the Atlantic Canada Opportunities Agency, under the AtlanticInnovation Fund, in support of the development of diagnostics for identifying specific subsets of cancer patient populations that would most likely benefit from receivingDepoVax™-based vaccines, DPX 0907 and DPX-Survivac. The funding will also be used by Immunovaccine to develop additional methods for measuring vaccine activity, to aidin the design of future phase II trials.
